Renal Cell Carcinoma | 58806

உடல்நலம் மற்றும் மருத்துவ ஆராய்ச்சி இதழ்


Renal Cell Carcinoma

Shavy Nagpal

Research focus: Investigating Olaparib, a selective inhibitor
of human poly (ADP-ribose) polymerase enzymes
(PARP-1, PARP2 and PARP-3) in renal cell carcinoma.
Approved by Health Canada for BRCA mutation positive
ovarian cancer, and germline BRCA – mutated
HER2 – negative metastatic breast cancer. Research focus
on DNA repair gene mutations and studying its therapeutic
Renal Cell Carcinoma is among 10th most common
cancer in both genders with a mortality of 4,970 out of
14,830 among women. 1 in 82 women are diagnosed with
renal cell carcinoma which accounts for about (1.02%). It
can present either alone or concomitant with other solid
tumors such as, breast and ovarian cancer. My research
area is investigating the role of BRCA mutations/ DNA
repair gene mutations (BAP 1 – BRCA associated protein
1 in renal cancer) that share an overlapping occurrence.
This is used to develop novel therapeutic pathways that
can possibly improve overall progression free survival,
and quality of life for our patients. We will talk about
modifiable and non – modifiable risk factors, and how
the latter can be pro – actively improved through novel research/
clinical trials. The presentation will also walk you
through a real case management of concomitant breast
(first diagnosis), and renal cell carcinoma (concomitant
diagnosis). Thank you for your time, and please feel free
to have your questions ready for me.